Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas - A randomized clinical trial

British Journal of Dermatology

Volumn 172, Issue 1, 2015, Pages 215-222

  Haak, C S ^a,b   Togsverd Bo, K ^a   Thaysen Petersen, D ^a   Wulf, H C ^a   Paasch, U ^c   Anderson, R R ^b   Haedersdal, M ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABLATIVE FRACTIONAL LASER MEDIATED PHOTODYNAMIC THERAPY; ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER RECURRENCE; CARBON DIOXIDE LASER; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LASER; LIGHT EMITTING DIODE; LOW LEVEL LASER THERAPY; MALE; PATIENT SAFETY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN BIOPSY; VERY ELDERLY; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CARCINOMA, BASAL CELL; CONTROLLED STUDY; DEVICES; FACIAL NEOPLASMS; FLUORESCENCE; GAS LASER; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; PROCEDURES; RISK FACTOR; SKIN NEOPLASMS; THERAPEUTIC USE; TREATMENT OUTCOME;

AMINOLEVULINIC ACID; METHYL 5-AMINOLEVULINATE; PHOTOSENSITIZING AGENT;

ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; CARCINOMA, BASAL CELL; COMBINED MODALITY THERAPY; FACIAL NEOPLASMS; FEMALE; FLUORESCENCE; HUMANS; LASER THERAPY; LASERS, GAS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RISK FACTORS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84920845423     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13166     Document Type: Article

References (43)

1. Nestor MS, Zarraga MB,. The incidence of nonmelanoma skin cancers and actinic keratoses in South Florida. J Clin Aesthet Dermatol 2012; 5: 20-4.
2. WHO. Skin Cancers. 2012. Available at: http://www.who.int/uv/faq/skincancer/en/index1.html (last accessed 27 July 2014).
3. Lomas A, Leonardi-Bee J, Bath-Hextall F,. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166: 1069-80.
4. Faurschou A, Wulf HC,. Ecological analysis of the relation between sunbeds and skin cancer. Photodermatol Photoimmunol Photomed 2007; 23: 120-5.
5. Telfer NR, Colver GB, Morton CA,. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008; 159: 35-48.
6. Bath-Hextall FJ, Perkins W, Bong J, Williams HC,. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007; 24: CD003412.
7. Sterry W,. Guidelines: the management of basal cell carcinoma. Eur J Dermatol 2006; 16: 467-75.
8. Nast A, Grabbe S,. Editorial: Update guidelines dermatologic oncology. J Dtsch Dermatol Ges 2013; 11: 1.
9. Skaria AM,. Recurrence of basosquamous carcinoma after Mohs micrographic surgery. Dermatology 2010; 221: 352-5.
10. Kiiski V,. Risk factors for single and multiple basal cell carcinomas. Arch Dermatol 2010; 146: 848-55.
11. Morton CA, Szeimies RM, Sidoroff A, Braathen LR,. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications-actinic keratoses, Bowen's disease, basal cell carcinoma. J Eur Acad Dermatol Venereol 2013; 27: 536-44.
12. Christensen E, Warloe T, Kroon S, et al,. Guidelines for practical use of MAL-PDT in non-melanoma skin cancer. J Eur Acad Dermatol Venereol 2010; 24: 505-12.
13. Braathen LR, Szeimies RM, Basset-Seguin N, et al,. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol 2007; 56: 125-43.
14. Lehmann P,. Methyl aminolaevulinate-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. Br J Dermatol 2007; 156: 793-801.
15. Kennedy JC, Pottier RH,. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol, B 1992; 14: 275-92.
16. Fantini F, Greco A, Del Giovane C, et al,. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response. J Eur Acad Dermatol Venereol 2011; 25: 896-901.
17. Li Q, Gao T, Jiao B, et al,. Tumor thickness predicts long-term complete response of facial basal cell carcinomas in Asian skin types iv/v treated with methyl aminolaevulinate photodynamic therapy. Photomed Laser Surg 2011; 29: 501-7.
18. Cosgarea R, Susan M, Crisan M, et al,. Photodynamic therapy using topical 5-aminolaevulinic acid vs. surgery for basal cell carcinoma. J Eur Acad Dermatol Venereol 2013; 27: 980-4.
19. Foley P, Freeman M, Menter A, et al,. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol 2009; 48: 1236-45.
20. Rhodes LE, de Rie M, Enström Y, et al,. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 2004; 140: 17-23.
21. Rhodes LE, de Rie MA, Leifsdottir R, et al,. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 2007; 143: 1131-6.
22. Horn M, Wolf P, Wulf HC, et al,. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol 2003; 149: 1242-9.
23. Vinciullo C, Elliott T, Francis D, et al,. Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma. Br J Dermatol 2005; 152: 765-72.
24. Roozeboom MH, Aardoom MA, Nelemans PJ, et al,. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. J Am Acad Dermatol 2013; 69: 280-7.
25. Peng Q, Soler AM, Warloe T, et al,. Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol, B 2001; 62: 140-5.
26. Sandberg C, Halldin CB, Ericson MB, et al,. Bioavailability of aminolaevulinic acid and methylaminolaevulinate in basal cell carcinomas: a perfusion study using microdialysis in vivo. Br J Dermatol 2008; 159: 1170-6.
27. Martin A, Tope W, Grevelink JM, et al,. Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment. Arch Dermatol Res 1995; 287: 665-74.
28. Manstein D, Herron GS, Sink RK, et al,. Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg Med 2004; 34: 426-38.
29. Tannous Z,. Fractional resurfacing. Clin Dermatol 2007; 25: 480-6.
30. Laubach HJ, Tannous Z, Anderson RR, Manstein D,. Skin responses to fractional photothermolysis. Lasers Surg Med 2006; 38: 142-9.
31. 2 laser-assisted drug delivery. Lasers Surg Med 2010; 42: 113-22.
32. 2 laser pretreatment. Lasers Surg Med 2011; 43: 804-13.
33. Forster B, Klein A, Szeimies RM, Maisch T,. Penetration enhancement of two topical 5-aminolaevulinic acid formulations for photodynamic therapy by erbium:YAG laser ablation of the stratum corneum: continuous versus fractional ablation. Exp Dermatol 2010; 19: 806-12.
34. Lee WR, Shen SC, Pai MH, et al,. Fractional laser as a tool to enhance the skin permeation of 5-aminolevulinic acid with minimal skin disruption: a comparison with conventional erbium:YAG laser. J Control Release 2010; 145: 124-33.
35. Haak CS, Farinelli WA, Tam J, et al,. Fractional laser-assisted delivery of methyl aminolevulinate: impact of laser channel depth and incubation time. Lasers Surg Med 2012; 44: 787-95.
36. Haedersdal M, Togsverd-Bo K, Paasch U,. Case reports on the potential of fractional laser-assisted photodynamic therapy for basal cell carcinomas. Lasers Med Sci 2012; 27: 1091-3.
37. Lippert J, Smucler R, Vlk M,. Fractional carbon dioxide laser improves nodular basal cell carcinoma treatment with photodynamic therapy with methyl 5-aminolevulinate. Dermatol Surg 2013; 39: 1202-8.
38. Kuijpers DI, Thissen MR, Neumann MH,. Basal cell carcinoma: treatment options and prognosis, a scientific approach to a common malignancy. Am J Clin Dermatol 2002; 3: 247-59.
39. Wiegell SR, Haedersdal M, Philipsen PA, et al,. Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blinded study. Br J Dermatol 2008; 158: 740-6.
40. Sexton M, Jones DB, Maloney ME,. Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol 1990; 23: 1118-26.
41. Fiechter S, Skaria A, Nievergelt H, et al,. Facial basal cell carcinomas recurring after photodynamic therapy: a retrospective analysis of histological subtypes. Dermatology 2012; 224: 346-51.
42. Thissen MR, Schroeter CA, Neumann HA,. Photodynamic therapy with delta-aminolaevulinic acid for nodular basal cell carcinomas using a prior debulking technique. Br J Dermatol 2000; 142: 338-9.
43. Gerritsen MJ, Smits T, Kleinpenning MM, et al,. Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy. Dermatology 2009; 218: 193-202.